Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.
FDA
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Toronto saw the biggest growth in technology jobs of any North American city between 2015 and 2020, while Vancouver, British Columbia also made the top five.
The findings are a culmination of decades of genome DNA sequencing by Lyons and her team, which have resulted in a nearly 100% complete assembly of the cat genome.
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
Inflammation is an important protective mechanism if it can be controlled. This is a key component of Genti’s engineering and the secret to the potency of its Tregs.
In India, only 8.3% of the population is fully vaccinated, while Sudan, Myanmar, and Ethiopia all have blank spaces beside their names in that category.
Voyager’s primary focus will be on developing gene therapies for Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and pre-clinical research in spinal muscular atrophy and diseases linked to GBA1 mutations.
Tadataka “Tachi” Yamada, a former GlaxoSmithKline and Takeda Pharmaceutical executive, early gene therapy backer, and philanthropist, passed away on Wednesday of natural causes at the age of 76.
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The United States and other wealthy nations now stand at an important place in their COVID-19 vaccine campaigns. The question largely turns to vaccinating the remainder of the population – namely, those under 12 years.
The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.
The T cell response was measured with immunoSEQ® T-MAP™ COVID, a clinical test developed by Adaptive Biotechnologies.